On Tuesday, the 2nd U.S. Circuit Court of Appeals in New York threw out a verdict fining two Chinese companies $147.8 million. The fine was given to Hebei Welcome Pharmaceutical Co and North China Pharmaceutical Group Corp for conspiring to fix prices and the supply of Vitamin C from December 2001 to June 2006.
The court stated that the case should never have gone to trial after China issued a statement to the presiding judge that Chinese laws required the companies to violate the Sherman Act. The Court of Appeals said that the judge who issued the fine should have deferred to China’s interpretation of its own laws since there are enormous differences between US and Chinese legal and economic regulations.
Full Content: CNBC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
CMA Launches Phase 2 Probe into AlphaTheta’s Acquisition of Serato
May 16, 2024 by
CPI
NFL Executive Escapes Testifying in High-Stakes Trial Over Televised Games
May 16, 2024 by
CPI
EU Consumers Lodge Complaint Against Chinese Retailer Temu Over Content Rules Breach
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI